Inflammatory response to cardiopulmonary bypass - Mechanisms involved and possible therapeutic strategies

被引:668
作者
Wan, S
LeClerc, JL
Vincent, JL
机构
[1] FREE UNIV BRUSSELS, DEPT INTENS CARE, ERASME UNIV HOSP, B-1070 BRUSSELS, BELGIUM
[2] FREE UNIV BRUSSELS, DEPT CARDIAC SURG, ERASME UNIV HOSP, B-1070 BRUSSELS, BELGIUM
关键词
antioxidants; aprotinin; cardiac surgery; complement; corticosteroids; cytokine; endothelin; endotoxin; inflammatory response; heat shock; heparin; leukocyte; ultrafiltration;
D O I
10.1378/chest.112.3.676
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Background: Recent study of the inflammatory reactions occurring during and after cardiopulmonary bypass (CPB) has improved our understanding of the involvement of the inflammatory cascade in perioperative injury, However, the exact mechanisms of this complex response remain to be fully determined, Methods: Literature on the inflammatory response to CPB was reviewed to define current knowledge on the possible pathways and mediators involved, and to discuss recent developments of therapeutic interventions aimed at attenuating the inflammatory response to CPB. Results: CPB has been shown to induce complement activation, endotoxin release, leukocyte activation, the expression of adhesion molecules, and the release of many inflammatory mediators including oxygen-free radicals, arachidonic acid metabolites, cytokines, platelet-activating factor, nitric oxide, and endothelins. Therapies aimed at interfering with the inflammatory response include the administration of pharmacologic agents such as corticosteroids, aprotinin, and antioxidants, as well as modification of techniques and equipment by the use of heparin-coated CPB circuits, intraoperative leukocyte depletion, and ultrafiltration, Conclusions: improved understanding of the inflammatory reactions to CPB can lead to improved patient outcome by enabling the development of novel therapies aimed at limiting this response.
引用
收藏
页码:676 / 692
页数:17
相关论文
共 235 条
[1]   INHALED NITRIC-OXIDE IN THE TREATMENT OF POSTOPERATIVE GRAFT DYSFUNCTION AFTER LUNG TRANSPLANTATION [J].
ADATIA, I ;
LILLIHEI, C ;
ARNOLD, JH ;
THOMPSON, JE ;
PALAZZO, R ;
FACKLER, JC ;
WESSEL, DL .
ANNALS OF THORACIC SURGERY, 1994, 57 (05) :1311-1318
[2]  
AHARINEJAD S, 1995, J THORAC CARDIOV SUR, V110, P148
[3]  
Aldea GS, 1996, ANN THORAC SURG, V62, P410, DOI 10.1016/0003-4975(96)00249-4
[4]  
Andersen L W, 1989, J Cardiothorac Anesth, V3, P544, DOI 10.1016/0888-6296(89)90150-6
[5]   ASSOCIATION BETWEEN GASTRIC INTRAMUCOSAL PH AND SPLANCHNIC ENDOTOXIN, ANTIBODY TO ENDOTOXIN, AND TUMOR-NECROSIS-FACTOR-ALPHA CONCENTRATIONS IN PATIENTS UNDERGOING CARDIOPULMONARY BYPASS [J].
ANDERSEN, LW ;
LANDOW, L ;
BAEK, L ;
JANSEN, E ;
BAKER, S .
CRITICAL CARE MEDICINE, 1993, 21 (02) :210-217
[6]  
ANDERSEN LW, 1987, J THORAC CARDIOV SUR, V93, P115
[7]  
BALLMER PE, 1994, J THORAC CARDIOV SUR, V108, P311
[8]  
BANDO K, 1990, J THORAC CARDIOV SUR, V99, P873
[9]   THE ROLE OF THE GUT IN THE DEVELOPMENT OF MULTIPLE ORGAN DYSFUNCTION IN CARDIOTHORACIC PATIENTS [J].
BAUE, AE .
ANNALS OF THORACIC SURGERY, 1993, 55 (04) :822-829
[10]   PLASMA ENDOTHELIN AND EARLY CORONARY ENDOTHELIAL DYSFUNCTION IN RECIPIENTS OF A CARDIAC TRANSPLANT [J].
BERKENBOOM, G ;
GIOT, C ;
UNGER, P ;
VACHIERY, JL ;
ANTOINE, M ;
LECLERC, JL .
AMERICAN HEART JOURNAL, 1995, 129 (06) :1178-1184